Applications
News & Events
Contact
Viral Vector R&D and Scale-up Solutions Viral Vector R&D and Scale-up Solutions
Cell Therapy Manufacturing Solutions Cell Therapy Manufacturing Solutions
Interdisciplinary Biotechnology R&D Platforms Interdisciplinary Biotechnology R&D Platforms

Solutions

Viral Vector R&D and Scale-up Solutions

With a focus on pioneering research in the CGT industry, EurekaBio strives to address unresolved core viral vector production challenges.

EuLV™ System

Solutions

Cell Therapy Manufacturing Solutions

EurekaBio offers comprehensive solutions for the preparation and production of cell therapy products, driving cost reduction and enhancing efficiency within the CGT industry.

CellSep™ PRO CellSep™ MAX

Platforms

Interdisciplinary Biotechnology R&D Platforms

By integrating automation and biotechnology, EurekaBio designs and builds automated platforms for biological research and development projects.

EuBioX System

Learn More

Development of AntiCD19-CAR Stable Producer Cell Line for Lentiviral Vector Production

In this case study, we used the EuLV™ system to develop an AntiCD19-CAR stable producer cell line. Additionally, we established a high-density culture process in chemically defined medium with low uninduced leakage of producer cells. The results of this study serve as proof of concept, demonstrating that the EuLV™ system can produce high-titer and high-quality lentiviral vectors.
EuLV™ System

Boosting Clinical Pipeline: EurekaBio CAS Enhances High-Quality TCR-T Sample Acquisition

A domestic leading cell therapy company is currently preparing to apply for IND for its TCR-T pipeline, one of its main pipelines. Among them, in the cell processing stage, they want to acheive the domestic replacement of automated equipment and focus on automating the processing of blood samples to concentrate cells, remove platelets, and separate PBMCs.
CellSep™ PRO

Cost-Effective Inducible Lentiviral Vector Production System Reducing LVV Cost in CAR-T Therapy

Lentivirus is one of the widely used viral vectors in cell & gene therapy. Our client, a leading CAR-T therapeutic company in China, utilizes lentiviral vectors to deliver specific T-cell receptor genes into patient-derived T cells. Seeking a more cost-effective solution for large-scale lentiviral vector production, our client adopted the EuLV™ stable producer cell line system to produce lentiviral vectors. 
EuLV™ System
We are always here to assist.

News Center

Learn More

2024.09.17

EurekaBio Earns Silver Rating from EcoVadis for remarkable sustainability performance

2024.04.30

Connect with EurekaBio at ASGCT 27th Annual Meeting

2024.03.07

EurekaBio Completes $40 Million Series B+ Financing to Advance EuLV™ Lentiviral Vector Production System

2023.08.10

Connect with EurekaBio at 2023 CAR-TCR Summit

2023.05.07

A Delegation from the Cell and Gene Therapy Product Regulation Research Committee under the China Society for Drug Regulation Visits EurekaBio for Research and Guidance

2023.05.06

EurekaBio Secures Two Awards of “2023 Future Healthcare VB100”

2023.04.18

EurekaBio Facilitating IND Application Filings and Advancing the Commercialization of CGT Drugs

2023.03.15

EurekaBio Accredited as a “Specialized and Sophisticated Enterprise that Produces Novel and Unique Products” in Shenzhen
Footer

Our story starts here…..

© 2024 Shenzhen Eureka Biotechnology Co., Limited. Privacy Policy

Viral Vector R&D and Scale-up Solutions

EuLV™ System

Cell Therapy Manufacturing Solutions

CellSep™ PRO

CellSep™ MAX

Applications News & Events Careers About Us

Interdisciplinary Biotechnology R&D Platforms

EuBioX System

Contact